<DOC>
	<DOCNO>NCT00740168</DOCNO>
	<brief_summary>Bevacizumab might influence dynamic vessel function administer intravenously .</brief_summary>
	<brief_title>Bevacizumab Treatment Retinal Vessel Monitoring</brief_title>
	<detailed_description>By monitor different vessel circulation parameter ( e.g . dynamic retinal vessel analyzer ) study clarify potential hemodynamic effect bevacizumab .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>patient wish need bevacizumab treatment underlie disease previous bevacizumab treatment know eye disease , eye surgery eye trauma history myopia &gt; 2.0 dpt hyperopia &gt; +2.0 dpt . relevant medium opacity lens acute heart disease , ischemic insult , proven coronary heart disease cardiac arrhythmia vessel anomaly seizure disorder episode history migraine treatment corticosteroid within 4 week study inclusion intake vasoactive drug like AT1 glitazone pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>cancer</keyword>
</DOC>